Clinical trials: Renal Transplant Rejection
Kidney Transplantation
Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation
The aim of this study is to determine whether a single dose of eculizumab can effectively prevent antibody-mediated rejection in recipients undergoing living donor kidney transplantation with a different ABO blood group type than…
- Trial name
- NCT06453135
- Testing
- Eculizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tao Lin
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
Kidney Transplantation
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation
The objective of the study will be to evaluate the effect of different therapeutic immunosuppressive strategies currently employed in common clinical practice on regulatory T lymphocytes and to verify the hypothesis that the…
- Trial name
- EVERTWIST (NCT01640743)
- Testing
- Tacrolimus + Methylprednisolone, Tacrolimus + Everolimus + Methylprednisolone
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Kidney Transplantation
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with…
- Trial name
- NCT00782821
- Testing
- Rabbit Antithymocyte Globulin, Velcade, Rituxan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Renal Transplant
B Cell Lymphocyte in Humoral Rejection and Alloimmunisation
This study aims to better characterise B cell phenotype and functional abnormalities in kidney transplant patients producing donor specific antibody (DSA) and in those with chronic antibody mediated rejection (cAMR) and to search…
- Trial name
- BHL (NCT03016455)
- Testing
- Presence of DSA w/ cAMR, Presence of DSA w/o cAMR, No DSA No cAMR
- Where
- 13 sites in France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Brest
Kidney Transplant Rejection
SRDK0921_ Analytical Performance Study
Analytical Performance Study of the SRDK0921 IVD medical device (Kit and Software)
- Trial name
- SRDK0921_APS (NCT05747274)
- Testing
- SRDK0921
- Where
- France
- Volunteers
- 439 people
- Sponsor
- BioMAdvanced Diagnostics
Kidney Transplant, Renal Transplant Failure
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage.
- Conditions
- Kidney Transplant, Renal Transplant Failure, Kidney Transplant Rejection, Frailty
- Trial name
- HLA-AB (NCT06025240)
- Testing
- cf-DNA, Immunological Events following renal transplant in older age, Determining Predictive Models for Post-transplant HLA-specific Antibody Formation
- Where
- United Kingdom
- Volunteers
- 282 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Kidney Transplantation
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
The principal purpose is the study of the regulation of the expression of ephrin-B1 by immunofluorescence in kidney biopsies of patients with Chronic transplant glomerulopathy (CTG) compared to biopsies prior to the CTG, in same…
- Trial name
- GARRE (NCT02147210)
- Testing
- biological analysis
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Kidney Rejection Transplant
Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study
Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years).
- Trial name
- NCT07091214
- Where
- France
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplantation
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not…
- Trial name
- NCT00896012
- Testing
- Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University at Buffalo
Renal Transplantation
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
To compare renal allograft rejection rates during the first year among high-immunological risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.
- Trial name
- TAXI (NCT00682292)
- Testing
- Thymoglobulin (ATG), Daclizumab
- Where
- France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Lille
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Kidney Transplantation
Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
Imlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs.
- Trial name
- ISKIA (NCT07379957)
- Where
- 20 sites in France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Bordeaux
Renal Disease
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to kidney transplantation.
- Trial name
- NCT02426684
- Testing
- IdeS® (Imlifidase)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Transplant Rejection
Immune Response in Desensitized Patients
Kidney transplantation is the best treatment for chronic renal failure in terms of morbidity and mortality, quality of life for patients and health economics.
- Trial name
- DELIGHT (NCT05785936)
- Testing
- Desensitization
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Clotting Disorder Due to Plasma Exchange Therapy, Humoral Rejection After Kidney Transplantation
Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange
Plasma exchange is a frequently used therapy in many antibody-mediated disorders, such as humoral rejection after kidney transplantation.
- Trial name
- NCT02095821
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Hannover Medical School
Delayed Graft Function, Renal Outcome After Kidney Transplantation
Volatile Anesthetic Protection Of Renal Transplants 2
To compare the effect of a sevoflurane based anesthesia versus a propofol based anesthesia on the incidence of DGF in recipients of kidneys of donation after circulatory death (DCD) and donation after brain death (DBD) donors
- Conditions
- Delayed Graft Function, Renal Outcome After Kidney Transplantation, Acute Rejection (AR) of Transplanted Kidney, Graft Survival
- Trial name
- VAPOR-2 (NCT02727296)
- Testing
- sevoflurane, propofol
- Where
- 5 sites in Denmark, Netherlands and 2 more
- Volunteers
- 488 people
- Sponsor
- University Medical Center Groningen
Urinary Tract Infections, Kidney Transplant Rejection
PRObiotics for KIdney Transplantation
The goal of this clinical trial is to assess if dietary supplememtation with OMNi-BiOTiC® 41167 reduces the risk of urinary tract infections in kidney transplant recipients.
- Conditions
- Urinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, Dysbiosis
- Trial name
- ProKiT (NCT06825117)
- Testing
- OMNi-BiOTiC® 41167
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- University Hospital, Udine, Italy